VIAADISCスコアによる再発性多発性硬化症における治療の緩和/中止後の疾患再活性化のリスクの階層化
Gabriel Bsteh1, Vincenzo Introcaso2, Christiane Gradl3
1Department of Neurology, Medical University of Vienna, Austria; Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Austria.
Multiple sclerosis and related disorders
|August 22, 2025
まとめ
VIAADISCスコアは,再発性多発性硬化症 (RMS) 患者の疾患修正療法 (DMT) を中止した後の疾患再活性化を予測します. より低いスコアは,特にディメチルフーマレートとテリフルーノミドのリスクが低いことを示し,高いスコアは,ナタリズマブとフィンゴリモドのリスクが高いことを示します.
科学分野:
- 神経学
- 免疫学
- 臨床試験
背景:
- 再発性多発性硬化症 (RMS) の治療には,疾患修正療法 (DMT) が含まれる.
- RMSでのDMTの緩和または中止は,病気の再活性化に対する注意深いリスク評価を必要とします.
- DMTの減量/中止の決定を導くために予測ツールが必要である.
研究 の 目的:
- DMTの減量または中止後のRMS患者の疾患再活性化を予測するVIAADISCスコアの能力を評価する.
- 患者の特徴と以前のDMTに基づいて再活性化リスクを分層する.
主な方法:
- RMS患者129人を対象に,DMTを減量/中止した後の分析.
- VIAADISCスコアの計算は,年齢,MRI活動,および臨床安定期間に基づいて行われます.
- 病気の再活性化 (再発および/または障害の進行) を評価するために,平均6. 0年の追跡調査.
主要な成果:
- ナタリズマブ (NTZ) またはフィンゴリモド (FTY) の中止後により高い割合で,患者の55. 0%で疾患再活性化が発生しました.
- より高いVIAADISCスコアは,独立した病気の再活性化 (HR 1. 25ポイント) を予測します.
- VIAADISC < 2でディメチルフーマラート (DMF) やテリフルノミド (TERI) を中止した際には再活性化は見られなかった.
結論:
- VIAADISCスコアは,DMF/TERIの中止に対する再活性化リスクを分層化し,長期的に安定した高齢患者の安全性を示唆する.
- NTZ/FTYからのデエスカレーションは,再活性化の高いリスクを持ち,横方向のスイッチを中止よりも好ましい戦略にします.
- VIAADISCスコアは,RMSにおけるDMT管理のための個別化されたリスク評価に役立ちます.
関連する概念動画
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Relative Risk
342
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
342
Atherosclerosis IV: Nursing Management
50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Mitral Valve Prolapse II: Assessment and Management
39
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39
Drug Administration and Therapy Phases: Overview
738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738


